Trade Royalty Pharma plc - RPRX CFD

About Royalty Pharma plc

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Royalty Pharma plc revenues increased 8% to $2.29B. Net income applicable to common stockholders increased 25% to $619.7M. Revenues reflect Income from financial royalty assets increase of 5% to $2.07B, Other royalty income increase from $19M to $53.1M, Revenue from intangible royalty assets increase of 19% to $171.2M. Net income benefited from Other operating expenses decrease from $65.1M (expense) to $0K.